Kelowna, BC – November 19, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, reports that final dosing has been completed on schedule with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo's® (“Novo”) commercially available Wegovy® tablets, over a 5-week duration (the “Study”). Final visits were completed this week by all Study participants within all Study arms. With dosing complete and final blood samples taken, the Study work will now shift to laboratory sample analyses, quality control and review of all data, and then reporting.








